Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyorin Gains Rights to Merck’s OAB Med in Asia
April 12, 2017
- Japan Authorized Generic Market Projected to Reach 81.7 Billion Yen in 2020: Fuji Keizai
April 11, 2017
- Takeda Sells Actos, Other Long-Listed Brands to Teva JV
April 11, 2017
- Ethical Drug Sales Sag 11.3% in February: Crecon
April 11, 2017
- Sumitomo Dainippon Gives Bukwang Korean Rights for Lurasidone
April 11, 2017
- Santen Makes Strategic Investment in US Cell Therapy Technology Firm
April 10, 2017
- Mogamulizumab Hits Primary Endpoint in PIII for CTCL: Kyowa Kirin
April 10, 2017
- Kyowa Kirin’s KRN23 Delivers Positive PII Data for Pediatric X-Linked Hypophosphatemia
April 10, 2017
- Takeda-PRA Joint Venture in Japan to Be Formed on June 1
April 10, 2017
- Trerief Delivers Positive Results in Lewy Body Dementia: Sumitomo Dainippon
April 7, 2017
- Boehringer Japan to Spur Joint Drug Discovery Research, Eyes 1st Clinical Trial in 2020
April 7, 2017
- Takeda Earns Global Rights to Finch’s Microbiome IBD Therapy
April 7, 2017
- Takeda’s Massive Dengue Trial Enrollment Completed
April 7, 2017
- Heptares Gains Preclinical Milestone in AZ Immuno-Oncology Deal
April 6, 2017
- Eisai Gets Japan, Asian Rights to Safinamide from Meiji
April 6, 2017
- Actelion’s Flolan Generic Outstrips Originator in Pediatric Use with Rare Dosage Nod; Japan Chief Says Company Fulfilling Maker’s Responsibility
April 6, 2017
- Mochida Aims for Sales of 107 Billion Yen in FY2017 under New 3 Year Biz Plan
April 5, 2017
- Daiichi Sankyo Sells US Packaging Plant
April 5, 2017
- Bayer Yakuhin Running Pilot AI Program for Sales Rep Support
April 5, 2017
- MSD Japan President Pins High Hopes on Keytruda Growth in 2017 after 7.8% Sales Dip
April 5, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…